This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HCA Healthcare (HCA) Rises 24.8% in a Year: More Room to Run?
by Zacks Equity Research
HCA Healthcare's (HCA) growing equivalent admissions are supporting performance.
The Joint (JYNT) to Report Q4 Earnings: Here Are the Key Drivers
by Zacks Equity Research
The Joint's (JYNT) fourth-quarter 2023 results are likely to reflect higher expenses and patient volumes.
5 Valuable Low Price-to-Sales Stocks to Refresh Your Portfolio
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like TAP, PAGS, CI, STT and FHN hold promise.
Centene (CNC), Pyx Health Unite to Treat Mental Health Issues
by Zacks Equity Research
Centene (CNC) partners with Pyx Health to address loneliness and mental health issues among the insured.
CI vs. HUM: Which Stock Is the Better Value Option?
by Zacks Equity Research
CI vs. HUM: Which Stock Is the Better Value Option?
If You Invested $1000 in Cigna a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Why Cigna (CI) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Humana (HUM) Collaborates With Veda to Enhance Efficiency
by Zacks Equity Research
Humana (HUM) partners with Veda to enhance the quality of provider directories.
Is Cigna Group (CI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Cigna (CI) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Cigna Group (CI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cigna (CI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Brookdale Senior's (BKD) Q4 Loss Widens, Shares Drop 13%
by Zacks Equity Research
Brookdale Senior's (BKD) Q4 results were hit by inflationary challenges, an increase in facility operating lease expense and higher income tax provision. It expects adjusted EBITDA within $90-$95 million in first-quarter 2024.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cigna (CI) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cigna (CI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
These 3 Companies Recently Provided Rosy Guidance
by Derek Lewis
Positive guidance is one of the most bullish announcements shareholders can hear, injecting confidence in the future picture. And that's precisely what these three companies have announced.
Centene (CNC) to Provide Better Health Equity in North Carolina
by Zacks Equity Research
Centene (CNC) collaborates with Reinvestment Partners to improve the health of North Carolinians.
Zacks Industry Outlook Highlights Cigna, Centene and Molina Healthcare
by Zacks Equity Research
Cigna, Centene and Molina Healthcare have been highlighted in this Industry Outlook article.
3 HMO Stocks in Focus Despite High Tech Costs & Nursing Shortage
by Debasmita Chatterjee
Growing customer base and M&A strategies are likely to aid the Medical-HMO industry. However, escalating expenses and a dearth in the availability of medical personnel are concerning. Stocks like CI, CNC and MOH are likely to navigate the industry storms.
Dividend Watch: 3 Companies Boosting Payouts
by Derek Lewis
Companies that boost their dividend payouts reflect a successful and shareholder-friendly nature, opting to share a portion of profits with investors. Who doesn't like payday?
Molina Healthcare (MOH) Q4 Earnings Beat on Premium Growth
by Zacks Equity Research
Molina Healthcare (MOH) expects adjusted EPS to be at a minimum of $23.5 in 2024, which represents a year-over-year improvement of 12.5%.
Cigna Group (CI) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cigna (CI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Cencora (COR) and Cigna (CI) have performed compared to their sector so far this year.
5 Stocks to Watch That Recently Announced Dividend Hikes
by Ritujay Ghosh
PACCAR Inc (PCAR), Church & Dwight Co., Inc. (CHD), Imperial Oil Limited (IMO), Ramaco Resources, Inc. (METC) and The Cigna Group (CI) recently hiked their dividends.
Centene (CNC) Q4 Earnings Beat on Membership Growth, View Up
by Zacks Equity Research
Centene (CNC) expects adjusted EPS to be a minimum of $6.70 in 2024, higher than the 2023 figure of $6.68 per share.
Cigna (CI) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Analyst Blog Highlights Meta Platforms, Eaton, The Cigna, Colgate-Palmolive and Parker-Hannifin
by Zacks Equity Research
Meta Platforms, Eaton, The Cigna, Colgate-Palmolive and Parker-Hannifin are included in this Analyst Blog.